Clinical Trials Logo

Filter by:
NCT ID: NCT03362424 Suspended - Rotator Cuff Tear Clinical Trials

Mesenchymal Stem Cells in Rotator Cuff Repair

Start date: November 1, 2020
Phase: Phase 2
Study type: Interventional

Randomized clinical study involving 44 patients, evaluating the effect of mesenchymal cells on rotator cuff repair. The primary outcome will be post-operative MRI tendon integrity and secondary outcomes clinical assessment by the UCLA and American Shoulder and Elbow Surgeons (ASES) scales and pain by visual analog scale (VAS).

NCT ID: NCT03362177 Active, not recruiting - Clinical trials for Chemotherapy-induced Thrombocytopenia

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

RECITE
Start date: September 30, 2019
Phase: Phase 3
Study type: Interventional

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer

NCT ID: NCT03362099 Completed - Smoking Cessation Clinical Trials

Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)

GENTSMOKING
Start date: November 1, 2016
Phase: Phase 4
Study type: Interventional

Smoking is the leading cause of avoidable death in the world. Smoking is associated with the development of cardiovascular and respiratory diseases, as well as being considered a leading cause of cancer death. Data show that smokers have increased cardiovascular risk in relation to former smokers, even in comparison with individuals who have had a long and intense history tobacco use. Considering this scenario, some drugs are used in tobacco cessation therapy. The first-line anti-smoking treatments approved by the Food and drug administration ( FDA ) are nicotinic reuptake therapy, bupropion ( norepinephrine and dopamine reuptake inhibitor) and varenicline ( partial agonist of nicotinic receptors composed of subunits alpha4Beta2 ). A metanalysis of 16 clinical studies indicated that smokers treated with bupropion had a higher abstinence rate compared to those receiving placebo - Odds ratio (OR ) - of 1,97 for treatment success. Varenicline is more effective compared to others smoking cessation drugs approved by the FDA, with an OR of 2,27 ( IC 95% 2,02-2,55 ) compared to placebo. However, Varenicline is much more expensive than bupropion. Significant advances in genetics have made the variability of the individual response to drugs, as far as efficacy as well as the rate of adverse effects, begin to be specifically investigated through pharmacogenetics studies.

NCT ID: NCT03361241 Completed - Stroke Clinical Trials

Comparison of Training in Virtual Environment With and Without Physiotherapeutic Intervention in Chronic Stroke Patients

Start date: April 2, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to compare the effects of balance training in a virtual environment with and without physiotherapeutic intervention on the motor function, balance and gait in chronic stroke patients. It is a prospective, single blinded, randomized clinical trial performed at Center of Research of the Department of Speech Therapy, Physical Therapy and Occupational Therapy of São Paulo University. Forty patients will be randomly assigned in control and experimental group.

NCT ID: NCT03360513 Completed - Clinical trials for Dental Arch Relationship Anomaly

Determining Shapes and Dimensions of Dental Arches for the Use in Lingual Technique.

Start date: August 1, 2016
Phase:
Study type: Observational

This study aims to determine the shape and dimension of dental arches from a lingual perspective, and determine shape and size used for lingual Orthodontics.

NCT ID: NCT03360500 Recruiting - Osteoarthritis,Knee Clinical Trials

Cryotherapy Associated With Exercise in Pain Control and Physical Function in Individuals With Knee Osteoarthritis

Start date: March 26, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to verify the effect of cryotherapy associated with an exercise protocol in pain control, function and quality of life in individuals with knee osteoarthritis

NCT ID: NCT03360487 Recruiting - Multiple Sclerosis Clinical Trials

Effect of Photobiomodulation Treatment in Individuals With Multiple Sclerosis:

Start date: January 1, 2018
Phase: Phase 2
Study type: Interventional

Background: Multiple sclerosis (MS) is an autoimmune disease, for which the forms of treatment are medication and rehabilitation. However, in vitro and in vivo studies have demonstrated that photobiomodulation can be an effective treatment modality for inflammatory diseases, including MS. Photobiomodulation has a broad range of benefits, such as the avoidance of cell and tissue death, the stimulation of healing and injury repair, reductions in pain, edema and inflammation, cell proliferation and even apoptosis. The outcomes of photobiomodulation include the regeneration of cells, the stimulation of the growth of Schwann cells, a reduction in spasticity, functional improvements, a reduction in nitric oxide levels and the upregulation of the cytokine IL10, demonstrating that this therapeutic modality can offer neuro-protection. Methods: A randomized, controlled, double-blind, clinical trial is proposed. The patients will be divided into six groups. Groups 1 and 2 will receive sham and active photobiomodulation in the sublingual region, respectively. Groups 3 and 4 will receive sham and active photobiomodulation along the spinal cord, respectively. Group 5 will receive placebo treatment with photobiomodulation on the skin in the region of the radial artery with a specific bracelet. Group 6 will be treated with photobiomodulation on the skin in the region of the radial artery with a specific bracelet. Discussion: Treatment for MS is directed at the immune response and slowing the progression of the disease. This is one of the first clinical trials with sublingual and along the spinal cord photobiomodulation, which could help establish a new, promising treatment of the disease associated with pharmacological treatment.

NCT ID: NCT03359551 Completed - Choroideremia Clinical Trials

Natural History of the Progression of Choroideremia Study

NIGHT
Start date: June 30, 2015
Phase:
Study type: Observational

The objective of this natural history study is to gain a better understanding of the progression of choroideremia (CHM) and add to the knowledge base for this rare disease.

NCT ID: NCT03359213 Completed - Clinical trials for Mucopolysaccharidosis II

A Study of JR-141 in Patients With Mucopolysaccharidosis II

Start date: July 26, 2018
Phase: Phase 2
Study type: Interventional

A Phase II open-label, randomized, parallel group, 2 sites (Brazil), designed to evaluate the safety and efficacy of 3 doses of study drug for the treatment of the MPS II.

NCT ID: NCT03359200 Completed - Clinical trials for Intraocular Pressure

Analysis of the Microbiota in Goldmann Applanation Tonometers at a Reference Service in Goiânia

Start date: September 1, 2017
Phase: N/A
Study type: Observational

This study aims to evaluate the microbiota of goldmann tonometers and its possible change over the visits